Anna Stölting

Anna Stölting

Auto-generated profile, based on publicly available information

Anna Stölting

Neuroinflammation Imaging Lab (NIL), Institute of NeuroScience, Université catholique de Louvain, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
SBSerena Borrelli
Serena Borrelli
MMMaria Sofia Martire
Maria Sofia Martire
ASAnna Stölting
Anna Stölting
CBColin Vanden Bulcke
Colin Vanden Bulcke
EPEdoardo Pedrini
Edoardo Pedrini
PMPietro Maggi
Pietro Maggi
The diagnosis of multiple sclerosis (MS) can be challenging in clinical practice because MS presentation can be atypical and mimicked by other diseases. We evaluated the diagnostic performance, alone or in combination, of the central vein sign (CVS), paramagnetic rim lesion (PRL), and cortical lesion (CL), as well as their association with clinical outcomes. In this multicenter observational study, we first conducted a cross-sectional analysis of the CVS (proportion of CVS-positive lesions or simplified determination of CVS in 3/6 lesions-Select3*/Select6*), PRL, and CL in MS and non-MS cases on 3T-MRI brain images, including 3D T2-FLAIR, T2*-echo-planar imaging magnitude and phase, double inversion recovery, and magnetization prepared rapid gradient echo image sequences. Then, we longitudinally analyzed the progression independent of relapse and MRI activity (PIRA) in MS cases over the 2 years after study entry. Receiver operating characteristic curves were used to test diagnostic performance and regression models to predict diagnosis and clinical outcomes. The presence of ≥41% CVS-positive lesions/≥1 CL/≥1 PRL (optimal cutoffs) had 96%/90%/93% specificity, 97%/84%/60% sensitivity, and 0.99/0.90/0.77 area under the curve (AUC), respectively, to distinguish MS (n = 185) from non-MS (n = 100) cases. The Select3*/Select6* algorithms showed 93%/95% specificity, 97%/89% sensitivity, and 0.95/0.92 AUC. The combination of CVS, CL, and PRL improved the diagnostic performance, especially when Select3*/Select6* were used (93%/94% specificity, 98%/96% sensitivity, 0.99/0.98 AUC; p = 0.002/p < 0.001). In MS cases (n = 185), both CL and PRL were associated with higher MS disability and severity. Longitudinal analysis (n = 61) showed that MS cases with >4 PRL at baseline were more likely to experience PIRA at 2-year follow-up (odds ratio 17.0, 95% confidence interval: 2.1-138.5; p = 0.008), whereas no association was observed between other baseline MRI measures and PIRA, including the number of CL. The combination of CVS, CL, and PRL can improve MS differential diagnosis. CL and PRL also correlated with clinical measures of poor prognosis, with PRL being a predictor of disability accrual independent of clinical/MRI activity.

9 October 2024 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
ASAnna Stölting
Anna Stölting
CBColin Vanden Bulcke
Colin Vanden Bulcke
SBSerena Borrelli
Serena Borrelli
CBCéline Bugli
Céline Bugli
RPRenaud Du Pasquier
Renaud Du Pasquier
PMPietro Maggi
Pietro Maggi
Objective: Previous studies reveal heterogeneity in terms of paramagnetic rim lesions (PRL) associated tissue damage. We investigated the physiopathology and clinical implications of this heterogeneity.Methods: In 103 MS patients (72 relapsing and 31 progressive), brain lesions were manually segmented on 3T 3D‐FLAIR and rim visibility was assessed with a visual confidence level score (VCLS) on 3D‐EPI phase. Using T1 relaxation time maps, lesions were categorized in long‐T1 and short‐T1. Lesion age was calculated from time of first gadolinium enhancement (N = 84 lesions). Results on clinical scores were validated in an extended cohort of 167 patients using normalized T1w‐MPRAGE lesion values.Results: Rim visibility (VCLS analysis) was associated with increasing lesional T1 (P/PFDR < 0.001). Of 1680 analyzed lesions, 427 were categorized as PRL. Long‐T1 PRL were older than short‐T1 PRL (average 0.8 vs. 2.0 years, P/PFDR = 0.005/0.008), and featured larger lesional volume (P/PFDR < 0.0001) and multi‐shell diffusion‐measured axonal damage (P/PFDR < 0.0001). The total volume of long‐T1‐PRL versus PRL showed 2× predictive power for both higher MS disability (EDSS; P/PFDR = 0.003/0.005 vs. P/PFDR = 0.042/0.057) and severity (MSSS; P/PFDR = 0.0006/0.001 vs. P/PFDR = 0.004/0.007). In random forest, having ≥1 long‐T1‐PRL versus ≥4 PRL showed 2‐4× higher performance to predict a higher EDSS and MSSS. In the validation cohort, long‐T1 PRL outperformed (~2×) PRL in predicting both EDSS and MSSS.Interpretation: PRL show substantial heterogeneity in terms of intralesional tissue damage. More destructive, likely older, long‐T1 PRL improve the association with MS clinical scales. This PRL heterogeneity characterization was replicated using standard T1w MRI, highlighting its potential for clinical translation.

23 August 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
MWMaxence Wynen
Maxence Wynen
PGPedro M. Gordaliza
Pedro M. Gordaliza
MIMaxime Istasse
Maxime Istasse
ASAnna Stölting
Anna Stölting
PMPietro Maggi
Pietro Maggi
MCMeritxell Bach Cuadra
Meritxell Bach Cuadra
Accurate lesion-level segmentation on MRI is critical for multiple sclerosis (MS) diagnosis, prognosis, and disease monitoring. However, current evaluation practices largely rely on semantic segmentation post-processed with connected components (CC), which cannot separate confluent lesions (aggregates of confluent lesion units, CLUs) due to reliance on spatial connectivity. To address this misalignment with clinical needs, we introduce formal definitions of CLUs and associated CLU-aware detection metrics, and include them in an exhaustive instance segmentation evaluation framework. Within this framework, we systematically evaluate CC and post-processing-based Automated Confluent Splitting (ACLS), the only existing methods for lesion instance segmentation in MS. Our analysis reveals that CC consistently underestimates CLU counts, while ACLS tends to oversplit lesions, leading to overestimated lesion counts and reduced precision. To overcome these limitations, we propose ConfLUNet, the first end-to-end instance segmentation framework for MS lesions. ConfLUNet jointly optimizes lesion detection and delineation from a single FLAIR image. Trained on 50 patients, ConfLUNet significantly outperforms CC and ACLS on the held-out test set (n = 13) in instance segmentation (Panoptic Quality: 42.0% vs. 37.5%/36.8%; p = 0.017/0.005) and lesion detection (F1: 67.3% vs. 61.6%/59.9%; p = 0.028/0.013). For CLU detection, ConfLUNet achieves the highest textF1CLU (81.5%), improving recall over CC (+12.5%, p = 0.015) and precision over ACLS (+31.2%, p = 0.003). By combining rigorous definitions, new CLU-aware metrics, a reproducible evaluation framework, and the first dedicated end-to-end model, this work lays the foundation for lesion instance segmentation in MS.

3 March 2026 in Brain Communications
Verified
Journal Article
Open access
PDF file
MWMaxence Wynen
Maxence Wynen
CBColin Vanden Bulcke
Colin Vanden Bulcke
SBSerena Borrelli
Serena Borrelli
PGPedro M Gordaliza
Pedro M Gordaliza
ASAnna Stölting
Anna Stölting
PMPietro Maggi
Pietro Maggi
Multiple sclerosis diagnostic criteria lack optimal specificity, leading to potential misdiagnosis. Advanced magnetic resonance imaging (MRI) biomarkers like the central vein sign, cortical lesions and paramagnetic rim lesions are highly specific to multiple sclerosis and could potentially improve diagnostic accuracy. In this study, we applied machine learning techniques to a retrospective, multicentric dataset of 322 multiple sclerosis/multiple sclerosis-mimic (204/118) and 84 prodromal multiple sclerosis/non-multiple sclerosis (43/41) adult patients, incorporating the central vein sign, cortical lesions and paramagnetic rim lesions. We compared (5 × 2 cross-validation combined F-test) the diagnostic performance of 71 machine learning models, each corresponding to a distinct combination of full-count or simplified biomarker inputs, against the baseline dissemination in space McDonald criteria. The aim was to evaluate the multiple sclerosis diagnostic power of combining these biomarkers in an MRI-only diagnostic framework. 51 of the 71 models significantly outperformed the dissemination in space criterion (P < 0.05), with balanced accuracy improvements up to 13.0% (confidence interval: [+10.5; +17.0]). The best overall model (random forest, using full-count assessments) achieved 95.7% (confidence interval: [93.2; 99.7]) balanced accuracy; the best simplified model (logistic regression, using only simplified assessments) reached 94.7% with no significant difference with the former (P = 0.29). Notably, 12/51 high-performing models used only simplified assessments. To further investigate the models’ generalizability, external validation on two out-of-distribution test sets using bootstrapping (1000 resamples) confirmed these results and highlighted a more robust generalization for the best model using solely simplified biomarkers. On the first external test set (n = 37, Verona), the simplified model achieved 97.2% balanced accuracy, while the full-count model reached 93.3% (versus 83.3% for baseline). On the second test set (n = 84, prodromal cases), the simplified model achieved 92.6% (versus 60.1% for baseline) showing competitive performance against the full-count model (93.9%). Both models improved all key performance metrics—balanced accuracy, sensitivity, specificity, precision and F1 score—over the baseline on both test sets (all P < 0.0001). Within a non-invasive MRI-only diagnostic framework, these results show that the incorporation of advanced imaging biomarkers into the multiple sclerosis-MRI diagnostic criteria significantly enhances the diagnostic accuracy—a statement holding true even when using simplified central vein sign, cortical lesions and paramagnetic rim lesions assessments. The study also provides a publicly available online diagnostic tool, facilitating further interaction, validation and clinical support (https://www.msdiagnostictool.org).

26 December 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
SBSerena Borrelli
Serena Borrelli
FGFrançois Guisset
François Guisset
MFMilena Farneti
Milena Farneti
ASAnna Stölting
Anna Stölting
CBColin Vanden Bulcke
Colin Vanden Bulcke
PMPietro Maggi
Pietro Maggi
Introduction: Diet is increasingly recognized as a potential factor influencing MS pathophysiology. Objective: To examine associations between diet and clinical/imaging/laboratory biomarkers of MS-related burden. Methods: In this cross-sectional study, daily nutrient intake was quantified in 112 MS patients using the French MetaCardis food frequency questionnaire. Participants underwent matched serum and 3T brain magnetic resonance imaging (MRI), including brain volumetrics, brain-predicted age, cortical lesions (CL), central vein sign (CVS), paramagnetic rim lesions (PRLs), and enlarged perivascular space (EPVS) assessments. p -values were false discovery rate corrected (pFDR), and regression models adjusted for energy intake and potential confounders. Results: Participants (66% women, 72% relapsing-remitting MS) had a median age of 42 years (interquartile range (IQR) = 20), disease duration of 9 years (20), body mass index (BMI) of 22.8 (5.3) kg/m², and expanded disability status scale (EDSS) of 2 (2.5). Saturated and trans-fatty acids intake were positively associated with anxiety symptoms (β = 0.39, pFDR = 0.02; β = 13.09, pFDR = 0.03, respectively).Alcohol intake was positively associated with EPVS score (β = 0.02, pFDR = 0.01), whereas trans-fatty acid intake was positively associated with CL count (β = 17.50, pFDR = 0.04) and PRL volume (β = 3251.37, pFDR = 0.04). Conclusion: Higher intake of saturated and trans-fatty acids and alcohol was associated with biomarkers of chronic inflammation and neurovascular dysfunction, suggesting a potential role in MS progression. Longitudinal and interventional studies are needed to establish causality.

1 November 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MDMatthieu Deltombe
Matthieu Deltombe
ASAnna Stölting
Anna Stölting
PMPietro Maggi
Pietro Maggi
Vincent van PeschVincent van Pesch
Vincent van Pesch
Fc receptor-like 5 (FCRL5) is an IgG-binding receptor frequently reported to be highly expressed on double-negative and atypical memory B cells, both of which are frequently expanded in inflammatory conditions. However, its expression profile in multiple sclerosis (MS) remains unclear. This study aims to characterize FCRL5 expression in CSF, serum, and peripheral blood mononuclear cells (PBMC) of patients with MS and to define the phenotypic and transcriptional features of FCRL5+ B cells in MS. A proximity extension assay-based proteomic analysis was conducted on the CSF of patients with relapsing-remitting MS (RRMS, n = 59) and controls (n = 29). The observed FCRL5 upregulation was validated using single-molecule array analysis in a cohort comprising patients with RRMS (n = 40), controls (n = 30), and individuals with other inflammatory neurologic diseases (OIND, n = 20). Serum FCRL5 levels were also assessed in a cohort of patients with MS characterized by 3T MRI (n = 58). In addition, flow cytometry-based techniques and RNA sequencing were performed on PBMC from patients with RRMS and controls to investigate the phenotype and transcriptional profiles of FCRL5+ B cells. Finally, the effect of Bruton tyrosine kinase inhibitors (BTKi) on FCRL5 regulation was also evaluated in vitro. FCRL5 was significantly upregulated in the CSF of patients with RRMS compared with that in controls and OIND. Elevated CSF FCRL5 levels were associated with an increased risk of new brain lesions within 24 months. Serum FCRL5 levels were not correlated with CSF measurements but were inversely correlated with the cortical and juxtacortical lesion burdens. Moreover, flow cytometry analysis revealed that peripheral CD19+FCRL5+ B cells of patients with RRMS differed from those of controls by their strong CD11c expression. The transcriptional profiles of CD19+CD11c+FCRL5+ cells also differed significantly between the 2 groups, characterized by reduced expression of humoral response genes and enhanced inflammatory signaling. In addition, FCRL5 regulation was found to be BTK-dependent. The soluble form of FCRL5 can be measured in the CSF and could serve as a promising biomarker for MS diagnosis and disease activity prediction. In addition, this study highlights that CD19+CD11c+FCRL5+ B cells in MS display a distinct transcriptional profile compared with controls.